Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.

Waldenström's macroglobulinemia (WM) is associated with a precursor condition, monoclonal gammopathy of undetermined significance (MGUS) of immunoglobulin-M (IgM) type. The etiology of these conditions is unknown. Recent studies at the population level have provided new data regarding familial aggregation of these disorders and other B-cell malignancies. Studies of familial clusters of WM have demonstrated an increased frequency of IgM MGUS compared with the general population and have provided new data suggesting that the phenotypic spectrum might also include polyclonal gammopathy and hypoglobulinemia. While the preponderance of immunoglobulin abnormalities in relatives of WM cases involves IgM, other immunoglobulin types (IgG and IgA) might also be affected. Large collaborative studies are needed to confirm these findings, which present an opportunity to define the earliest lesion(s) in the WM oncogenic pathway.

[1]  A. Rossi,et al.  Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Dimopoulos,et al.  Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece , 2002, Annals of Hematology.

[3]  M. Björkholm,et al.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. , 2008, Blood.

[4]  Stefan Boehringer,et al.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. , 2006, American journal of human genetics.

[5]  M. McMaster Familial Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[6]  G. Csako,et al.  Protein electrophoresis, immunoelectrophoresis and immunofixation electrophoresis as predictors for high‐risk phenotype in familial Waldenström macroglobulinemia , 2007, International Journal of Cancer.

[7]  M. Tucker,et al.  Long-term Evaluation of Three Multiple-Case Waldenström Macroglobulinemia Families , 2007, Clinical Cancer Research.

[8]  J. Fraumeni,et al.  Cancer epidemiology and prevention. , 2006 .

[9]  U. Axelsson,et al.  Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. , 2009, Acta medica Scandinavica.

[10]  M. Kraus,et al.  Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: one disease or three? , 2001, American journal of clinical pathology.

[11]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[12]  L. Melton,et al.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. , 2007, Mayo Clinic proceedings.

[13]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[14]  K. Hemminki,et al.  Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. , 2004, Blood.

[15]  J. Olsen,et al.  Familial Aggregation and Heterogeneity of Non-Hodgkin Lymphoma in Population-Based Samples , 2005, Cancer Epidemiology Biomarkers & Prevention.

[16]  J. Koshiol,et al.  Chronic immune stimulation and subsequent Waldenström macroglobulinemia. , 2008, Archives of internal medicine.

[17]  S. Strobel Transient paraproteinemia: an intriguing immunological anomaly. , 2003, Annals of clinical and laboratory science.

[18]  H. Cohen,et al.  Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. , 1998, The American journal of medicine.

[19]  J. Fraumeni,et al.  Waldenström's macroglobulinemia , 1998, Cancer.

[20]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[21]  E. Jaffe Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[22]  M. Vicariot,et al.  Monoclonal gammopathies in the adult population of Finistère, France. , 1982, Journal of clinical pathology.

[23]  H. El‐Serag,et al.  Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. , 2007, JAMA.

[24]  T. Therneau,et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.

[25]  M. Tomonaga,et al.  Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. , 2007, Mayo Clinic proceedings.